Dyne Therapeutics (DYN) Liabilities and Shareholders Equity (2019 - 2026)

Dyne Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 49.77% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $3.9 billion (up 28.46% YoY), while the FY2025 annual figure was $1.2 billion, up 71.72% from the prior year.
• Liabilities and Shareholders Equity was $1.1 billion for Q1 2026 at Dyne Therapeutics, down from $1.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.2 billion in Q4 2025 to a low of $165.1 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $566.9 million across 5 years, with a median of $522.3 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 46.11% in 2023, then surged 318.72% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $306.3 million in 2022, then plunged by 46.11% to $165.1 million in 2023, then soared by 318.72% to $691.2 million in 2024, then jumped by 71.72% to $1.2 billion in 2025, then declined by 9.02% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $867.1 million (Q3 2025), per Business Quant data.